People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated ...

The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott ...

VX-880 stem cell therapy led to 92% reduction in insulin use, with 10 out of 12 patients eliminating injections entirely in a ...

Women with diabetes who were overweight or had obesity lost more weight and had greater odds of diabetes remission when ...

For adult women with overweight or obesity and type 2 diabetes (T2D), replacing diet beverages (DBs) with water is associated ...

Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Results presented at the 85th Scientific Sessions of the American Diabetes Association in Chicago highlight the potential for ...

All 3 doses of orforglipron superior to placebo with respect to primary end point of change in HbA1c from baseline to week 40.